Apogee Therapeutics, Inc. Intellectual Property Contracts & Agreements
9 Contracts & Agreements
- License Agreements (9 contracts)
- Third Amendment to License Agreement, dated June 10, 2024, by and between the Company and MIL 6T, LLC (Filed With SEC on August 12, 2024)
- Second Amendment to License Agreement, dated February 26, 2024, by and between the Company and MIL 6T, LLC (Filed With SEC on August 12, 2024)
- First Amendment to License Agreement, dated December 4, 2023, by and between the Company and MIL 6T, LLC (Filed With SEC on August 12, 2024)
- License Agreement, dated November 22, 2023, by and between the Company and MIL 6T, LLC (Filed With SEC on August 12, 2024)
- Cell Line License Agreement, effective as of June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on June 22, 2023)
- OX40L License Agreement, dated April 28, 2023, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- IL-4R License Agreement, dated April 3, 2023, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- Amendment No. 1 to IL-13 License Agreement, dated November 10, 2022, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
- IL-13 License Agreement, dated November 4, 2022, by and between Paragon Therapeutics, Inc. and Apogee Biologics, Inc. (f/k/a Apogee Therapeutics, Inc.) (Filed With SEC on June 22, 2023)
